This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Imax Diagnostic Imaging Holding Limited. Active years: 2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016
Introduction
Hongdeng Xing, an accomplished inventor based in Shanghai, China, has made significant contributions to the field of chemical processes. With a focus on innovations in pharmaceutical chemistry, he has developed a patented method that enhances the preparation of vital chemical compounds used in medical imaging.
Latest Patents
Xing holds a patent for his invention titled "Iodination process for the preparation of 3, 5-disubstituted-2, 4, 6-triiodo aromatic amines compounds." This enhanced iodination process provides a more efficient way to synthesize 3,5-disubstituted-2,4,6-triiodo aromatic amines, which are crucial intermediates in the production of non-ionic contrast agents like Iopamidol, Iohexol, and Iodixanol. The process employs chlorine-free iodinating reagents and boasts a remarkable molar yield of 89%, marking a significant improvement in the chemical synthesis landscape.
Career Highlights
Currently, Hongdeng Xing is affiliated with Imax Diagnostic Imaging Holding Limited, where he plays a critical role in research and development. His work has not only advanced the efficiency of chemical processes but also contributed to enhancing medical imaging techniques.
Collaborations
Throughout his career, Xing has collaborated with talented professionals such as Lei Li and Zhiqi Hu, fostering a productive environment to drive innovation within the company. Their collective expertise plays a vital role in advancing the company's mission and expanding its reach in the diagnostic imaging market.
Conclusion
In summary, Hongdeng Xing's innovative patent in iodination demonstrates his noteworthy contributions to the field of pharmaceutical chemistry. His dedication to improving chemical synthesis processes significantly impacts the development of non-ionic contrast agents, benefiting the medical community and enhancing patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile